Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytokine modifiers: pipe dream or reality?

E Abraham1

  • 1Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver 80262, USA. Edward.Abraham@UCHSC.edu

Chest
|March 27, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Near-infrared-terahertz hyper-Raman spectroscopy of an excited silicon surface.

The Journal of chemical physics·2024
Same author

Accessible and reliable neurometric testing in humans using a smartphone platform.

Scientific reports·2023
Same author

Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Ultrafast, broadband and tunable terahertz reflector and neutral density filter based on high resistivity silicon.

Optics express·2022
Same author

Mental health improvements after elective spine surgery: a Canadian Spine Outcome Research Network (CSORN) study.

The spine journal : official journal of the North American Spine Society·2021
Same author

Erratum to 'Patients' expectations of spine surgery for degenerative conditions: results from the Canadian Spine Outcomes and Research Network (CSORN)'. [Spine J. 2020;20(3):399-408].

The spine journal : official journal of the North American Spine Society·2020
Same journal

The effect of a two-day stay at high altitude (2500 m) on right ventricular afterload and oxygen delivery in patients with pulmonary vascular disease A randomized controlled crossover trial.

Chest·2026
Same journal

A Comparative Study of Radiation Exposure in Conventional and Robotic Bronchoscopy.

Chest·2026
Same journal

Independent Prognostic Contributions of Anti-Ro52 and Anti-MDA5 in Autoimmune-Associated Interstitial Lung Disease.

Chest·2026
Same journal

Lung aeration and gas exchange in SGA or AGA infants with moderate-severe BPD: secondary analysis of the PATH-BPD study.

Chest·2026
Same journal

Lung Cancer Incidence and Mortality after Negative Low-Dose CT Screening Results.

Chest·2026
Same journal

Symptom prevalence and impact on lung cancer risk in the SUMMIT study.

Chest·2026
See all related articles

Blocking tumor necrosis factor alpha (TNF-alpha) may improve survival in severe sepsis patients. Interleukin-1 (IL-1) blockers showed no benefit. Further trials are needed to confirm anti-TNF therapy effectiveness in sepsis treatment.

Area of Science:

  • Critical care medicine
  • Immunology
  • Pharmacology

Background:

  • Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection.
  • Cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-alpha), play key roles in sepsis pathogenesis.
  • Targeting these cytokines has been explored as a therapeutic strategy for sepsis.

Purpose of the Study:

  • To evaluate the efficacy of blocking IL-1 and TNF-alpha in critically ill patients with sepsis.
  • To determine if anticytokine therapies improve survival rates in sepsis.

Main Methods:

  • Review of clinical trials investigating IL-1 and TNF-alpha inhibition in sepsis.
  • Analysis of survival data in prospectively defined patient subgroups.

Related Experiment Videos

Main Results:

  • Therapies blocking IL-1 did not demonstrate survival benefits in sepsis patients.
  • Inhibition of TNF-alpha with monoclonal antibodies or receptor fusion proteins showed potential survival benefits in specific severe sepsis groups.
  • Statistically significant improvements in 28-day mortality were not consistently demonstrated across all trials, partly due to study power limitations.

Conclusions:

  • Anti-TNF therapies suggest improved survival in identifiable severe sepsis patient groups.
  • Confirmation of anti-TNF agent benefits requires results from ongoing large-scale, multicenter clinical trials.
  • Targeted cytokine inhibition remains an area of active research for sepsis management.